IDIndonesia is positioning itself as a regional hub for Advanced Therapy Medicinal Products (ATMP) by enhancing its regulatory framework and infrastructure for stem cell therapy. The head of Indonesia’s Food and Drug Authority (BPOM), Taruna Ikrar, highlighted the global growth of gene therapy, cell therapy, and RNA-based treatments, with over 4,164 ATMPs in development worldwide and 148 already approved. He noted the ATMP market is expected to grow significantly, reaching $86.76 billion by 2031. To support this, BPOM is implementing stricter regulations, certifying GMP facilities, and fostering collaborations between universities, businesses, and the government. The goal is to create an environment conducive to innovation while ensuring patient safety and regulatory compliance.
Procjena pristranosti (Sredina): The article presents a factual overview of Indonesia’s strategic initiative to develop its ATMP sector without overtly promoting any specific ideological stance. It focuses on economic and scientific development, citing data and expert statements without taking a clear partisan position. While the话题
Zašto ove ocjene (Činjenice 95 · Objektivnost 88): Factuality is high as the article reports on Indonesia's plans for ATMP development, citing specific figures like 4,164 ATMPs in development and a projected market growth. Objectivity is slightly lower due to the promotional tone around Indonesia's ambitions and the emphasis on positive outcomes wit
